Ibiayi Dagogo-Jack, MD

Articles

How Biomarker Testing Could Continue to Evolve in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.

Tissue vs Liquid Biopsies for Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.

Benefits of In-House Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.

Treatment Planning After Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.

The Specificity/Sensitivity of Rapid Lung NGS for Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.

The Utility of Rapid Lung NGS for Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the utility of Rapid Lung NGS for biomarker testing in NSCLC.

When to Conduct Molecular Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on when to conduct biomarker testing in NSCLC.

The Role of Biomarker Testing in Metastatic and Resectable NSCLC

November 8th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study

June 17th 2024

CROWN (NCT03052608) is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC.